Cambrex Announcing Progress in US and European Expansion Efforts

Cambrex, a global leader in contract development and manufacturing, has completed initial engineering studies for its new large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa. This marks a significant step in its $120 million investment plan to enhance U.S. API production. Construction is expected to start in late 2026.

The expansion in Charles City will include a new plant with 140,000 liters of capacity, featuring advanced reactors and equipment. This new facility will boost the site's large-scale manufacturing capacity by 20%, catering to complex chemistries and positioning Cambrex as a key partner in pharmaceutical innovation.

In Europe, Cambrex is also progressing with a $30 million expansion at its Milan, Italy site, set to enhance analytical development and process R&D. This project, anticipated to conclude in late 2027, highlights Cambrex's commitment to meeting rising demands for advanced CDMO services.